REGENXBIO Inc. (RGNX) CEO Ken Mills on Q1 2021 Results - Earnings Call Transcript

May 05, 2021 9:44 PM ETREGENXBIO Inc. (RGNX) StockRGNX
SA Transcripts
153.96K Followers

Q1: 2021-05-05 Earnings Summary

EPS of -$1.20 beats by $0.02
 | Revenue of $18.88M (7.03% Y/Y) misses by $4.36M

REGENXBIO Inc. (NASDAQ:RGNX) Q1 2021 Results Conference Call May 5, 2021 4:30 PM ET

Company Participants

Patrick Christmas - Chief Legal Officer
Ken Mills - President and CEO
Dr. Steve Pakola - Chief Medical Officer

Conference Call Participants

Alec Stranahan - Bank of America
Gena Wang - Barclays
Gbola Amusa - Chardan
Esther Rajavelu - UBS
Kostas Biliouris - Morgan Stanley
Lisa Walter - RBC

Operator

Good afternoon, and welcome to the REGENXBIO First Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. As a reminder, this conference call is being recorded.

I would now like to turn the call over to Mr. Patrick Christmas, Chief Legal Officer of REGENXBIO. You may begin.

Patrick Christmas

Good afternoon, and thank you for joining us.

With us today are Ken Mills, REGENXBIO’s President and Chief Executive Officer; and Dr. Steve Pakola, our Chief Medical Officer.

Earlier this afternoon, REGENXBIO released financial and operating results for the first quarter ended March 31, 2020. The press release reporting our financial results is available on our website at www.regenxbio.com.

Today’s conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted, and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend and other words of similar meaning.

Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the Risk Factors and the Management’s Discussion and Analysis sections of REGENXBIO’s annual report on Form 10-K for the full year ended December 31, 2020, and comparable

Recommended For You

About RGNX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on RGNX